In the field of biomarker research, the term “tumor mutation burden” (TMB) refers to a prediction of the amount of mutations carried by tumor cells. The cancer cell now has a distinct fingerprint of natural and altered proteins, which may be measured using TMB.
Our researchers have created a brand-new algorithmic method for tumor mutational burden analysis to determine the effectiveness of checkpoint inhibitor treatment. Our researchers can count the number of acquired somatic mutations that are present in tumors but not in healthy tissues by comparing the DNA sequences from a patient’s tumor cells and healthy tissues. We are certain that we will offer consumers the greatest service at the most affordable price.